| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sepsis | 19 | 2023 | 71 | 6.860 |
Why?
|
| Intensive Care Units | 24 | 2023 | 106 | 6.720 |
Why?
|
| Hospital Mortality | 29 | 2023 | 150 | 5.730 |
Why?
|
| Critical Care | 11 | 2022 | 73 | 4.090 |
Why?
|
| Electronic Health Records | 23 | 2022 | 747 | 3.780 |
Why?
|
| Humans | 143 | 2023 | 18430 | 3.610 |
Why?
|
| Hospitalization | 22 | 2022 | 847 | 3.280 |
Why?
|
| Critical Illness | 8 | 2021 | 53 | 3.210 |
Why?
|
| Retrospective Studies | 54 | 2023 | 2550 | 2.900 |
Why?
|
| Male | 78 | 2023 | 10440 | 2.300 |
Why?
|
| Delivery of Health Care, Integrated | 17 | 2022 | 567 | 2.240 |
Why?
|
| Aged | 59 | 2022 | 6417 | 2.150 |
Why?
|
| Middle Aged | 60 | 2022 | 8284 | 2.130 |
Why?
|
| Female | 79 | 2022 | 13136 | 2.110 |
Why?
|
| Anti-Bacterial Agents | 7 | 2022 | 142 | 2.070 |
Why?
|
| Clinical Deterioration | 4 | 2022 | 5 | 2.010 |
Why?
|
| Inpatients | 10 | 2022 | 80 | 1.950 |
Why?
|
| Adult | 50 | 2023 | 7910 | 1.860 |
Why?
|
| California | 31 | 2021 | 2365 | 1.740 |
Why?
|
| Artificial Intelligence | 3 | 2022 | 14 | 1.730 |
Why?
|
| Pneumonia, Viral | 4 | 2021 | 57 | 1.670 |
Why?
|
| Quality Improvement | 6 | 2022 | 207 | 1.610 |
Why?
|
| Respiratory Distress Syndrome, Adult | 3 | 2016 | 9 | 1.580 |
Why?
|
| Patient Readmission | 10 | 2022 | 162 | 1.540 |
Why?
|
| Aged, 80 and over | 28 | 2021 | 2003 | 1.520 |
Why?
|
| Hospitals | 10 | 2023 | 80 | 1.510 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 50 | 1.500 |
Why?
|
| Outcome Assessment (Health Care) | 8 | 2016 | 254 | 1.500 |
Why?
|
| Severity of Illness Index | 10 | 2021 | 476 | 1.460 |
Why?
|
| Betacoronavirus | 3 | 2020 | 36 | 1.430 |
Why?
|
| Emergency Service, Hospital | 13 | 2022 | 382 | 1.370 |
Why?
|
| Length of Stay | 11 | 2022 | 183 | 1.350 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2022 | 22 | 1.330 |
Why?
|
| Postoperative Care | 3 | 2022 | 20 | 1.310 |
Why?
|
| Health Plan Implementation | 3 | 2019 | 41 | 1.240 |
Why?
|
| Analgesics, Opioid | 3 | 2019 | 241 | 1.240 |
Why?
|
| Patient Transfer | 3 | 2020 | 24 | 1.200 |
Why?
|
| Machine Learning | 6 | 2022 | 44 | 1.170 |
Why?
|
| Health Maintenance Organizations | 5 | 2020 | 479 | 1.100 |
Why?
|
| Lung Transplantation | 3 | 2011 | 7 | 1.080 |
Why?
|
| Fluid Therapy | 4 | 2016 | 11 | 1.070 |
Why?
|
| Lactic Acid | 3 | 2016 | 9 | 1.040 |
Why?
|
| Respiration, Artificial | 4 | 2023 | 38 | 1.020 |
Why?
|
| Patient Acuity | 2 | 2022 | 7 | 1.010 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2020 | 350 | 1.000 |
Why?
|
| Risk Adjustment | 4 | 2018 | 32 | 0.980 |
Why?
|
| Delivery of Health Care | 4 | 2023 | 444 | 0.950 |
Why?
|
| Forecasting | 3 | 2020 | 80 | 0.940 |
Why?
|
| Family | 2 | 2017 | 120 | 0.940 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 3 | 2023 | 4 | 0.910 |
Why?
|
| Models, Theoretical | 3 | 2022 | 76 | 0.910 |
Why?
|
| Disease Transmission, Infectious | 2 | 2020 | 13 | 0.890 |
Why?
|
| Cohort Studies | 20 | 2023 | 2672 | 0.870 |
Why?
|
| Pain, Postoperative | 2 | 2019 | 16 | 0.860 |
Why?
|
| Sezary Syndrome | 2 | 2023 | 2 | 0.860 |
Why?
|
| Algorithms | 4 | 2020 | 241 | 0.830 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2022 | 4 | 0.820 |
Why?
|
| Pain Management | 2 | 2019 | 59 | 0.810 |
Why?
|
| Ethanol | 1 | 2022 | 23 | 0.800 |
Why?
|
| Cost-Benefit Analysis | 2 | 2019 | 270 | 0.800 |
Why?
|
| Benzodiazepines | 1 | 2022 | 26 | 0.800 |
Why?
|
| Oxygen | 3 | 2022 | 16 | 0.790 |
Why?
|
| Skin Neoplasms | 3 | 2023 | 64 | 0.770 |
Why?
|
| Hospitals, Community | 3 | 2016 | 23 | 0.750 |
Why?
|
| Program Evaluation | 3 | 2021 | 244 | 0.740 |
Why?
|
| Risk Assessment | 11 | 2023 | 1143 | 0.730 |
Why?
|
| Treatment Outcome | 8 | 2022 | 1296 | 0.730 |
Why?
|
| Workload | 1 | 2020 | 30 | 0.720 |
Why?
|
| Equipment and Supplies, Hospital | 1 | 2020 | 2 | 0.720 |
Why?
|
| Elective Surgical Procedures | 2 | 2017 | 8 | 0.720 |
Why?
|
| Alcoholism | 3 | 2022 | 350 | 0.700 |
Why?
|
| Blood Culture | 1 | 2020 | 4 | 0.700 |
Why?
|
| Unsupervised Machine Learning | 1 | 2019 | 1 | 0.700 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2019 | 7 | 0.700 |
Why?
|
| Orthopedic Procedures | 1 | 2019 | 6 | 0.700 |
Why?
|
| Delirium | 2 | 2016 | 2 | 0.690 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2017 | 59 | 0.680 |
Why?
|
| Cesarean Section | 1 | 2019 | 30 | 0.680 |
Why?
|
| Clinical Protocols | 2 | 2017 | 45 | 0.670 |
Why?
|
| Comorbidity | 9 | 2022 | 619 | 0.660 |
Why?
|
| Erythrocyte Transfusion | 5 | 2019 | 9 | 0.650 |
Why?
|
| Risk Factors | 17 | 2023 | 3449 | 0.650 |
Why?
|
| Suicide | 1 | 2020 | 126 | 0.650 |
Why?
|
| Attitude of Health Personnel | 3 | 2020 | 226 | 0.650 |
Why?
|
| United States | 16 | 2022 | 4164 | 0.650 |
Why?
|
| Mycosis Fungoides | 1 | 2018 | 1 | 0.640 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2018 | 1 | 0.640 |
Why?
|
| Quality of Life | 2 | 2022 | 529 | 0.640 |
Why?
|
| Healthcare Disparities | 2 | 2011 | 211 | 0.640 |
Why?
|
| Natural Language Processing | 2 | 2016 | 57 | 0.630 |
Why?
|
| Patient Discharge | 5 | 2022 | 153 | 0.620 |
Why?
|
| Skin | 3 | 2007 | 14 | 0.620 |
Why?
|
| Cluster Analysis | 2 | 2017 | 96 | 0.620 |
Why?
|
| Hip Fractures | 2 | 2019 | 68 | 0.600 |
Why?
|
| Pneumonia | 3 | 2017 | 56 | 0.600 |
Why?
|
| Perioperative Care | 1 | 2017 | 4 | 0.600 |
Why?
|
| Rectum | 1 | 2017 | 12 | 0.590 |
Why?
|
| Colon | 1 | 2017 | 21 | 0.590 |
Why?
|
| Pandemics | 6 | 2023 | 292 | 0.590 |
Why?
|
| Venous Thromboembolism | 3 | 2023 | 52 | 0.590 |
Why?
|
| Quality of Health Care | 6 | 2021 | 347 | 0.590 |
Why?
|
| Prospective Studies | 8 | 2022 | 1314 | 0.580 |
Why?
|
| Inventions | 1 | 2017 | 2 | 0.570 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 530 | 0.570 |
Why?
|
| Infection | 2 | 2016 | 17 | 0.570 |
Why?
|
| State Health Plans | 1 | 2017 | 44 | 0.560 |
Why?
|
| Mortality | 7 | 2021 | 123 | 0.560 |
Why?
|
| Convalescence | 1 | 2016 | 2 | 0.550 |
Why?
|
| Writing | 1 | 2016 | 12 | 0.550 |
Why?
|
| Noninvasive Ventilation | 1 | 2016 | 10 | 0.550 |
Why?
|
| Life Support Care | 1 | 2016 | 4 | 0.550 |
Why?
|
| Medical Informatics | 1 | 2016 | 45 | 0.550 |
Why?
|
| Emergency Medical Services | 1 | 2016 | 47 | 0.540 |
Why?
|
| Patient Safety | 2 | 2016 | 41 | 0.540 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2022 | 72 | 0.540 |
Why?
|
| Dexmedetomidine | 1 | 2016 | 1 | 0.540 |
Why?
|
| Patient Preference | 1 | 2016 | 45 | 0.520 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 133 | 0.520 |
Why?
|
| Computer Security | 1 | 2015 | 8 | 0.510 |
Why?
|
| Facial Nerve | 1 | 2015 | 1 | 0.510 |
Why?
|
| Facial Paralysis | 1 | 2015 | 2 | 0.510 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 195 | 0.500 |
Why?
|
| Mental Disorders | 1 | 2018 | 295 | 0.500 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2015 | 14 | 0.500 |
Why?
|
| Crime | 1 | 2015 | 21 | 0.500 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2020 | 407 | 0.490 |
Why?
|
| Medical Records | 1 | 2015 | 106 | 0.490 |
Why?
|
| Thoracic Injuries | 1 | 2014 | 2 | 0.480 |
Why?
|
| Information Dissemination | 1 | 2014 | 57 | 0.470 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2013 | 3 | 0.460 |
Why?
|
| Research Design | 1 | 2016 | 402 | 0.460 |
Why?
|
| Patient Identification Systems | 1 | 2013 | 4 | 0.450 |
Why?
|
| Radiography, Thoracic | 1 | 2013 | 19 | 0.450 |
Why?
|
| Visitors to Patients | 1 | 2013 | 1 | 0.440 |
Why?
|
| Organizational Policy | 1 | 2013 | 17 | 0.440 |
Why?
|
| Iatrogenic Disease | 1 | 2012 | 8 | 0.420 |
Why?
|
| Survival Rate | 6 | 2018 | 269 | 0.410 |
Why?
|
| Kidney Failure, Chronic | 2 | 2022 | 151 | 0.410 |
Why?
|
| Benchmarking | 3 | 2021 | 45 | 0.410 |
Why?
|
| Health Care Surveys | 1 | 2013 | 247 | 0.410 |
Why?
|
| Models, Statistical | 6 | 2022 | 185 | 0.410 |
Why?
|
| Pneumonectomy | 1 | 2011 | 7 | 0.390 |
Why?
|
| European Continental Ancestry Group | 2 | 2011 | 554 | 0.390 |
Why?
|
| Time Factors | 5 | 2021 | 1136 | 0.390 |
Why?
|
| Heart Transplantation | 1 | 2011 | 11 | 0.380 |
Why?
|
| Medicare | 4 | 2022 | 214 | 0.380 |
Why?
|
| Clinical Laboratory Information Systems | 1 | 2010 | 2 | 0.370 |
Why?
|
| Hemoglobins | 4 | 2022 | 39 | 0.360 |
Why?
|
| Shock, Septic | 3 | 2016 | 9 | 0.360 |
Why?
|
| Postoperative Complications | 3 | 2017 | 103 | 0.360 |
Why?
|
| African Continental Ancestry Group | 1 | 2011 | 166 | 0.360 |
Why?
|
| Survival | 1 | 2010 | 5 | 0.360 |
Why?
|
| Lung Neoplasms | 2 | 2011 | 259 | 0.360 |
Why?
|
| Health Care Rationing | 1 | 2010 | 14 | 0.350 |
Why?
|
| Prognosis | 4 | 2021 | 624 | 0.350 |
Why?
|
| Phenytoin | 2 | 2020 | 4 | 0.350 |
Why?
|
| Cause of Death | 1 | 2011 | 185 | 0.350 |
Why?
|
| Cytochrome P-450 CYP2C9 | 2 | 2020 | 6 | 0.350 |
Why?
|
| Heart-Lung Transplantation | 1 | 2009 | 2 | 0.350 |
Why?
|
| Paramyxoviridae Infections | 1 | 2009 | 2 | 0.350 |
Why?
|
| Ribavirin | 1 | 2009 | 8 | 0.350 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2009 | 24 | 0.340 |
Why?
|
| Immunologic Factors | 1 | 2009 | 27 | 0.340 |
Why?
|
| Quality Indicators, Health Care | 3 | 2021 | 197 | 0.330 |
Why?
|
| Follow-Up Studies | 8 | 2021 | 1269 | 0.330 |
Why?
|
| Stroke | 2 | 2022 | 311 | 0.330 |
Why?
|
| Anemia | 2 | 2022 | 32 | 0.320 |
Why?
|
| Skin Diseases | 2 | 2007 | 10 | 0.320 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2008 | 1 | 0.320 |
Why?
|
| Linear Models | 3 | 2015 | 243 | 0.320 |
Why?
|
| Immunocompromised Host | 1 | 2008 | 20 | 0.310 |
Why?
|
| Adolescent | 8 | 2022 | 3798 | 0.310 |
Why?
|
| Liver Neoplasms | 1 | 2008 | 42 | 0.300 |
Why?
|
| Quinazolines | 1 | 2007 | 1 | 0.300 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2007 | 3 | 0.300 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2007 | 5 | 0.300 |
Why?
|
| Clostridium Infections | 2 | 2017 | 11 | 0.290 |
Why?
|
| Hospital Rapid Response Team | 2 | 2016 | 2 | 0.280 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 1389 | 0.280 |
Why?
|
| Early Diagnosis | 2 | 2016 | 40 | 0.280 |
Why?
|
| Patient Admission | 3 | 2019 | 76 | 0.280 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 365 | 0.270 |
Why?
|
| Logistic Models | 5 | 2019 | 962 | 0.260 |
Why?
|
| Pulmonary Embolism | 2 | 2015 | 44 | 0.250 |
Why?
|
| Sensitivity and Specificity | 4 | 2020 | 321 | 0.250 |
Why?
|
| Aftercare | 2 | 2022 | 48 | 0.240 |
Why?
|
| Vaccination | 3 | 2023 | 674 | 0.230 |
Why?
|
| Multivariate Analysis | 3 | 2020 | 598 | 0.230 |
Why?
|
| Disease Management | 2 | 2015 | 143 | 0.230 |
Why?
|
| Survivors | 2 | 2015 | 158 | 0.230 |
Why?
|
| Quarantine | 2 | 2021 | 10 | 0.230 |
Why?
|
| Information Storage and Retrieval | 2 | 2021 | 16 | 0.220 |
Why?
|
| Proportional Hazards Models | 5 | 2020 | 743 | 0.220 |
Why?
|
| Age Factors | 5 | 2020 | 965 | 0.220 |
Why?
|
| Photopheresis | 1 | 2023 | 1 | 0.220 |
Why?
|
| Insulin | 2 | 2022 | 208 | 0.220 |
Why?
|
| Pharmacogenomic Variants | 2 | 2020 | 7 | 0.220 |
Why?
|
| Bacteremia | 1 | 2023 | 15 | 0.220 |
Why?
|
| Community-Acquired Infections | 1 | 2023 | 24 | 0.210 |
Why?
|
| Frailty | 1 | 2022 | 9 | 0.210 |
Why?
|
| Coinfection | 1 | 2023 | 30 | 0.210 |
Why?
|
| Surgical Procedures, Operative | 1 | 2022 | 17 | 0.210 |
Why?
|
| Monitoring, Physiologic | 1 | 2022 | 41 | 0.210 |
Why?
|
| Crisis Intervention | 1 | 2022 | 16 | 0.210 |
Why?
|
| Insulin, Regular, Human | 1 | 2022 | 5 | 0.210 |
Why?
|
| Adamantane | 1 | 2012 | 6 | 0.200 |
Why?
|
| Dipeptides | 1 | 2012 | 6 | 0.200 |
Why?
|
| Outpatients | 1 | 2023 | 111 | 0.200 |
Why?
|
| Technology | 1 | 2021 | 7 | 0.200 |
Why?
|
| Child | 4 | 2022 | 2571 | 0.200 |
Why?
|
| HIV Infections | 1 | 2008 | 695 | 0.200 |
Why?
|
| Residence Characteristics | 2 | 2021 | 256 | 0.190 |
Why?
|
| Pressure Ulcer | 2 | 2018 | 5 | 0.190 |
Why?
|
| Computer Simulation | 1 | 2021 | 85 | 0.190 |
Why?
|
| Young Adult | 6 | 2021 | 2518 | 0.190 |
Why?
|
| Health Status | 3 | 2020 | 328 | 0.190 |
Why?
|
| Laboratory Critical Values | 2 | 2020 | 2 | 0.190 |
Why?
|
| Automobile Driving | 1 | 2020 | 10 | 0.190 |
Why?
|
| Automation | 3 | 2020 | 24 | 0.190 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 199 | 0.180 |
Why?
|
| Air Pollutants | 1 | 2021 | 52 | 0.180 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2020 | 12 | 0.180 |
Why?
|
| Air Pollution | 1 | 2021 | 42 | 0.180 |
Why?
|
| Patient Isolation | 1 | 2020 | 1 | 0.180 |
Why?
|
| Illinois | 1 | 2020 | 8 | 0.180 |
Why?
|
| Infection Control | 1 | 2020 | 10 | 0.180 |
Why?
|
| Societies | 1 | 2020 | 2 | 0.180 |
Why?
|
| Health Planning | 1 | 2020 | 17 | 0.180 |
Why?
|
| Cytochrome P-450 CYP2C19 | 1 | 2020 | 4 | 0.180 |
Why?
|
| Drug Eruptions | 1 | 2020 | 4 | 0.180 |
Why?
|
| Personnel, Hospital | 1 | 2020 | 9 | 0.180 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 11 | 0.180 |
Why?
|
| Academic Success | 1 | 2020 | 4 | 0.180 |
Why?
|
| Hospitals, Veterans | 1 | 2020 | 34 | 0.180 |
Why?
|
| Oximetry | 1 | 2020 | 3 | 0.180 |
Why?
|
| Mentors | 1 | 2020 | 12 | 0.180 |
Why?
|
| Terminology as Topic | 1 | 2020 | 21 | 0.180 |
Why?
|
| Psychometrics | 1 | 2020 | 124 | 0.180 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 43 | 0.180 |
Why?
|
| Social Class | 1 | 2020 | 125 | 0.170 |
Why?
|
| Data Collection | 4 | 2022 | 275 | 0.170 |
Why?
|
| Negotiating | 1 | 2019 | 4 | 0.170 |
Why?
|
| Myocardial Infarction | 1 | 2012 | 249 | 0.170 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 41 | 0.170 |
Why?
|
| Health Services for the Aged | 1 | 2019 | 15 | 0.170 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 112 | 0.170 |
Why?
|
| Health Priorities | 1 | 2019 | 28 | 0.170 |
Why?
|
| Consensus | 2 | 2016 | 41 | 0.170 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 288 | 0.160 |
Why?
|
| Ipilimumab | 1 | 2018 | 1 | 0.160 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 2 | 0.160 |
Why?
|
| Child, Preschool | 2 | 2022 | 1478 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 5 | 0.160 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2018 | 11 | 0.160 |
Why?
|
| Pruritus | 1 | 2018 | 3 | 0.160 |
Why?
|
| Symptom Assessment | 1 | 2018 | 6 | 0.160 |
Why?
|
| Positron-Emission Tomography | 1 | 2018 | 28 | 0.160 |
Why?
|
| Emotions | 1 | 2018 | 35 | 0.160 |
Why?
|
| Biomarkers | 2 | 2016 | 308 | 0.160 |
Why?
|
| Vasoconstrictor Agents | 2 | 2016 | 7 | 0.160 |
Why?
|
| Melanoma | 1 | 2018 | 37 | 0.160 |
Why?
|
| Fatal Outcome | 2 | 2008 | 4 | 0.160 |
Why?
|
| Income | 1 | 2018 | 98 | 0.150 |
Why?
|
| Skin Care | 1 | 2018 | 2 | 0.150 |
Why?
|
| Diagnosis, Differential | 3 | 2007 | 61 | 0.150 |
Why?
|
| Bloodless Medical and Surgical Procedures | 2 | 2014 | 2 | 0.150 |
Why?
|
| Dietary Services | 1 | 2017 | 2 | 0.150 |
Why?
|
| Emergencies | 1 | 2017 | 6 | 0.150 |
Why?
|
| Nutrition Therapy | 1 | 2017 | 4 | 0.150 |
Why?
|
| Early Ambulation | 1 | 2017 | 3 | 0.150 |
Why?
|
| Primary Prevention | 1 | 2018 | 79 | 0.150 |
Why?
|
| Needs Assessment | 1 | 2017 | 69 | 0.140 |
Why?
|
| Recurrence | 3 | 2017 | 187 | 0.140 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 630 | 0.140 |
Why?
|
| Drug Utilization | 1 | 2017 | 134 | 0.140 |
Why?
|
| Telemedicine | 1 | 2020 | 184 | 0.140 |
Why?
|
| Medically Uninsured | 1 | 2017 | 61 | 0.140 |
Why?
|
| Recovery of Function | 1 | 2016 | 28 | 0.140 |
Why?
|
| Reproducibility of Results | 4 | 2022 | 399 | 0.140 |
Why?
|
| International Classification of Diseases | 1 | 2016 | 87 | 0.140 |
Why?
|
| Evidence-Based Practice | 1 | 2016 | 56 | 0.140 |
Why?
|
| Patient Care Bundles | 1 | 2016 | 1 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2019 | 760 | 0.140 |
Why?
|
| Organ Dysfunction Scores | 1 | 2016 | 3 | 0.140 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 100 | 0.130 |
Why?
|
| Patient Participation | 1 | 2017 | 144 | 0.130 |
Why?
|
| Computational Biology | 1 | 2016 | 28 | 0.130 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 1360 | 0.130 |
Why?
|
| Attitude to Computers | 2 | 2006 | 15 | 0.130 |
Why?
|
| Computers, Handheld | 2 | 2006 | 11 | 0.130 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2015 | 1 | 0.130 |
Why?
|
| Betacellulin | 1 | 2015 | 1 | 0.130 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2015 | 3 | 0.130 |
Why?
|
| Health Services | 1 | 2016 | 117 | 0.130 |
Why?
|
| Genetic Therapy | 1 | 2015 | 8 | 0.130 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2015 | 9 | 0.130 |
Why?
|
| Phenotype | 1 | 2016 | 148 | 0.130 |
Why?
|
| Survival Analysis | 2 | 2018 | 226 | 0.130 |
Why?
|
| Incidence | 4 | 2021 | 1314 | 0.130 |
Why?
|
| Health Status Indicators | 1 | 2015 | 71 | 0.130 |
Why?
|
| Nerve Tissue Proteins | 1 | 2015 | 21 | 0.130 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2015 | 2 | 0.130 |
Why?
|
| Databases as Topic | 1 | 2015 | 22 | 0.130 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 214 | 0.130 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 160 | 0.120 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2015 | 56 | 0.120 |
Why?
|
| Cost Control | 1 | 2004 | 25 | 0.120 |
Why?
|
| Data Mining | 1 | 2014 | 20 | 0.120 |
Why?
|
| Quality Control | 1 | 2014 | 48 | 0.120 |
Why?
|
| Health Facilities | 1 | 2014 | 18 | 0.120 |
Why?
|
| Guideline Adherence | 1 | 2015 | 162 | 0.120 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 228 | 0.120 |
Why?
|
| Pregnancy | 1 | 2019 | 1516 | 0.120 |
Why?
|
| Physicians | 2 | 2013 | 141 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2016 | 1173 | 0.110 |
Why?
|
| Process Assessment (Health Care) | 1 | 2013 | 28 | 0.110 |
Why?
|
| Ambulatory Care | 1 | 2015 | 266 | 0.110 |
Why?
|
| Vasopressins | 1 | 2012 | 5 | 0.110 |
Why?
|
| Respiratory Insufficiency | 1 | 2012 | 16 | 0.100 |
Why?
|
| Probability | 2 | 2022 | 86 | 0.100 |
Why?
|
| Health Care Costs | 1 | 2004 | 251 | 0.100 |
Why?
|
| Managed Care Programs | 1 | 2014 | 347 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 2 | 2009 | 21 | 0.100 |
Why?
|
| Contraindications | 1 | 2011 | 15 | 0.100 |
Why?
|
| Odds Ratio | 1 | 2013 | 701 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2011 | 13 | 0.100 |
Why?
|
| Waiting Lists | 1 | 2011 | 12 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 131 | 0.090 |
Why?
|
| Multi-Institutional Systems | 1 | 2010 | 2 | 0.090 |
Why?
|
| Databases, Factual | 3 | 2017 | 327 | 0.090 |
Why?
|
| Diagnosis-Related Groups | 2 | 2020 | 27 | 0.090 |
Why?
|
| Pharmacogenomic Testing | 2 | 2020 | 4 | 0.090 |
Why?
|
| Palivizumab | 1 | 2009 | 2 | 0.090 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2009 | 8 | 0.090 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2009 | 17 | 0.090 |
Why?
|
| Respiratory Function Tests | 1 | 2009 | 32 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2009 | 26 | 0.090 |
Why?
|
| Forced Expiratory Volume | 1 | 2009 | 69 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 119 | 0.080 |
Why?
|
| Health Status Disparities | 1 | 2011 | 153 | 0.080 |
Why?
|
| Antiviral Agents | 1 | 2009 | 95 | 0.080 |
Why?
|
| Lymphatic Diseases | 1 | 2008 | 1 | 0.080 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2008 | 2 | 0.080 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 673 | 0.080 |
Why?
|
| Head | 1 | 2008 | 8 | 0.080 |
Why?
|
| Lymphatic Metastasis | 1 | 2008 | 29 | 0.080 |
Why?
|
| Regression Analysis | 2 | 2016 | 319 | 0.080 |
Why?
|
| Sex Factors | 3 | 2020 | 661 | 0.080 |
Why?
|
| Human Growth Hormone | 1 | 2008 | 2 | 0.080 |
Why?
|
| Athletic Performance | 1 | 2008 | 2 | 0.080 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2020 | 126 | 0.080 |
Why?
|
| Patient Care Planning | 1 | 2008 | 51 | 0.080 |
Why?
|
| Epidermis | 1 | 2007 | 1 | 0.080 |
Why?
|
| Skin Ulcer | 1 | 2007 | 2 | 0.080 |
Why?
|
| Stem Cell Transplantation | 1 | 2007 | 2 | 0.080 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2007 | 2 | 0.080 |
Why?
|
| Hyperplasia | 1 | 2007 | 6 | 0.080 |
Why?
|
| CD8 Antigens | 1 | 2007 | 2 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 150 | 0.080 |
Why?
|
| Eczema | 1 | 2007 | 7 | 0.080 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2008 | 178 | 0.080 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2007 | 1 | 0.080 |
Why?
|
| African Americans | 1 | 2011 | 490 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 50 | 0.070 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2008 | 95 | 0.070 |
Why?
|
| Neoplasm Staging | 1 | 2008 | 337 | 0.070 |
Why?
|
| Clostridium difficile | 2 | 2017 | 23 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 208 | 0.070 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2007 | 51 | 0.070 |
Why?
|
| Online Systems | 1 | 2006 | 8 | 0.070 |
Why?
|
| Pennsylvania | 2 | 2016 | 27 | 0.070 |
Why?
|
| Hypotension | 2 | 2016 | 5 | 0.070 |
Why?
|
| Influenza Vaccines | 1 | 2009 | 290 | 0.070 |
Why?
|
| Carbamazepine | 1 | 2005 | 4 | 0.070 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2005 | 4 | 0.070 |
Why?
|
| Influenza, Human | 1 | 2009 | 282 | 0.070 |
Why?
|
| Eosinophilia-Myalgia Syndrome | 1 | 2004 | 1 | 0.060 |
Why?
|
| Fibrosis | 1 | 2004 | 7 | 0.060 |
Why?
|
| Biopsy | 1 | 2004 | 75 | 0.060 |
Why?
|
| Single-Cell Analysis | 1 | 2023 | 2 | 0.060 |
Why?
|
| Bacteria | 1 | 2023 | 6 | 0.050 |
Why?
|
| Otitis Media | 1 | 2003 | 21 | 0.050 |
Why?
|
| Postoperative Period | 1 | 2022 | 16 | 0.050 |
Why?
|
| Frail Elderly | 1 | 2022 | 9 | 0.050 |
Why?
|
| Thrombolytic Therapy | 1 | 2022 | 21 | 0.050 |
Why?
|
| Dexamethasone | 1 | 2022 | 11 | 0.050 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 12 | 0.050 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2022 | 23 | 0.050 |
Why?
|
| Geriatric Assessment | 1 | 2022 | 40 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2022 | 44 | 0.050 |
Why?
|
| Pneumococcal Infections | 1 | 2003 | 53 | 0.050 |
Why?
|
| Brain | 1 | 2022 | 46 | 0.050 |
Why?
|
| Renal Dialysis | 1 | 2022 | 59 | 0.050 |
Why?
|
| Meningococcal Vaccines | 1 | 2003 | 46 | 0.050 |
Why?
|
| Reference Standards | 1 | 2022 | 17 | 0.050 |
Why?
|
| Pneumococcal Vaccines | 1 | 2003 | 80 | 0.050 |
Why?
|
| Drug Approval | 1 | 2012 | 14 | 0.050 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2012 | 8 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2012 | 36 | 0.050 |
Why?
|
| Poisson Distribution | 1 | 2012 | 94 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2022 | 125 | 0.050 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 54 | 0.050 |
Why?
|
| Confounding Factors (Epidemiology) | 1 | 2012 | 99 | 0.050 |
Why?
|
| Cognition | 1 | 2022 | 82 | 0.050 |
Why?
|
| Aerosols | 1 | 2021 | 1 | 0.050 |
Why?
|
| Normal Distribution | 1 | 2021 | 6 | 0.050 |
Why?
|
| APACHE | 1 | 2021 | 11 | 0.050 |
Why?
|
| Environmental Monitoring | 1 | 2021 | 26 | 0.050 |
Why?
|
| Particulate Matter | 1 | 2021 | 29 | 0.050 |
Why?
|
| Workflow | 1 | 2021 | 11 | 0.050 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2012 | 110 | 0.050 |
Why?
|
| Alert Fatigue, Health Personnel | 1 | 2020 | 1 | 0.050 |
Why?
|
| Telemetry | 1 | 2020 | 2 | 0.050 |
Why?
|
| China | 1 | 2021 | 130 | 0.050 |
Why?
|
| Nursing Staff, Hospital | 1 | 2020 | 12 | 0.050 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2020 | 6 | 0.050 |
Why?
|
| Risk Reduction Behavior | 1 | 2021 | 114 | 0.050 |
Why?
|
| Patient Care | 1 | 2021 | 36 | 0.050 |
Why?
|
| Surgery Department, Hospital | 1 | 2020 | 3 | 0.050 |
Why?
|
| HLA-B15 Antigen | 1 | 2020 | 2 | 0.050 |
Why?
|
| Role | 1 | 2020 | 3 | 0.050 |
Why?
|
| Faculty, Medical | 1 | 2020 | 10 | 0.040 |
Why?
|
| Professional Competence | 1 | 2020 | 12 | 0.040 |
Why?
|
| Molecular Epidemiology | 1 | 2020 | 44 | 0.040 |
Why?
|
| Alleles | 1 | 2020 | 95 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 120 | 0.040 |
Why?
|
| Blood Donors | 1 | 2019 | 1 | 0.040 |
Why?
|
| Blood Preservation | 1 | 2019 | 2 | 0.040 |
Why?
|
| Blood Specimen Collection | 1 | 2019 | 8 | 0.040 |
Why?
|
| Syncope | 1 | 2019 | 12 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 36 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 131 | 0.040 |
Why?
|
| Health Services Research | 1 | 2020 | 264 | 0.040 |
Why?
|
| Washington | 1 | 2020 | 388 | 0.040 |
Why?
|
| Hypoglycemia | 1 | 2019 | 49 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 2022 | 375 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2018 | 12 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 414 | 0.040 |
Why?
|
| Hispanic Americans | 1 | 2020 | 428 | 0.040 |
Why?
|
| Depression | 1 | 2022 | 518 | 0.040 |
Why?
|
| Fee-for-Service Plans | 1 | 2017 | 28 | 0.040 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2016 | 2 | 0.040 |
Why?
|
| Vital Signs | 1 | 2016 | 14 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2019 | 267 | 0.030 |
Why?
|
| Tachypnea | 1 | 2016 | 1 | 0.030 |
Why?
|
| Lactates | 1 | 2016 | 2 | 0.030 |
Why?
|
| Resuscitation | 1 | 2016 | 3 | 0.030 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2016 | 9 | 0.030 |
Why?
|
| Review Literature as Topic | 1 | 2016 | 13 | 0.030 |
Why?
|
| Risk | 1 | 2017 | 552 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2016 | 33 | 0.030 |
Why?
|
| Pharmacopoeias as Topic | 2 | 2006 | 2 | 0.030 |
Why?
|
| Reference Books, Medical | 2 | 2006 | 2 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2016 | 49 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2022 | 848 | 0.030 |
Why?
|
| Blood Pressure Determination | 1 | 2016 | 58 | 0.030 |
Why?
|
| Suppressor of Cytokine Signaling 1 Protein | 1 | 2015 | 1 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2015 | 1 | 0.030 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2015 | 1 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 1 | 0.030 |
Why?
|
| Immunosuppression | 1 | 2015 | 9 | 0.030 |
Why?
|
| Islets of Langerhans | 1 | 2015 | 12 | 0.030 |
Why?
|
| Liver | 1 | 2015 | 33 | 0.030 |
Why?
|
| Mice | 1 | 2015 | 68 | 0.030 |
Why?
|
| Outcome and Process Assessment (Health Care) | 1 | 2015 | 110 | 0.030 |
Why?
|
| Documentation | 1 | 2015 | 45 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2016 | 112 | 0.030 |
Why?
|
| Central Venous Pressure | 1 | 2014 | 1 | 0.030 |
Why?
|
| Animals | 1 | 2015 | 261 | 0.030 |
Why?
|
| Disease Progression | 1 | 2016 | 271 | 0.030 |
Why?
|
| Long-Term Care | 1 | 2014 | 22 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2004 | 468 | 0.030 |
Why?
|
| Skilled Nursing Facilities | 1 | 2014 | 8 | 0.030 |
Why?
|
| Calibration | 1 | 2014 | 8 | 0.030 |
Why?
|
| Medical Record Linkage | 1 | 2014 | 44 | 0.030 |
Why?
|
| Insurance Claim Review | 1 | 2014 | 70 | 0.030 |
Why?
|
| Interferon Type I | 1 | 1993 | 4 | 0.030 |
Why?
|
| Propensity Score | 1 | 2014 | 94 | 0.030 |
Why?
|
| Hepatitis B | 1 | 1993 | 43 | 0.030 |
Why?
|
| Autism Spectrum Disorder | 1 | 2016 | 164 | 0.030 |
Why?
|
| Physician's Role | 1 | 2012 | 32 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2012 | 198 | 0.030 |
Why?
|
| Selection Bias | 1 | 2009 | 24 | 0.020 |
Why?
|
| Basal Metabolism | 1 | 2008 | 5 | 0.020 |
Why?
|
| Muscle Strength | 1 | 2008 | 14 | 0.020 |
Why?
|
| Body Composition | 1 | 2008 | 82 | 0.020 |
Why?
|
| Software | 1 | 2006 | 21 | 0.020 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 2005 | 1 | 0.020 |
Why?
|
| Radiography | 1 | 2005 | 41 | 0.020 |
Why?
|
| Seizures | 1 | 2005 | 30 | 0.020 |
Why?
|
| Lung | 1 | 2005 | 62 | 0.020 |
Why?
|
| Medical Errors | 1 | 2005 | 17 | 0.020 |
Why?
|
| Reminder Systems | 1 | 2005 | 94 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 1983 | 2 | 0.010 |
Why?
|
| Exercise | 1 | 2008 | 495 | 0.010 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1983 | 9 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2003 | 3 | 0.010 |
Why?
|
| Middle Ear Ventilation | 1 | 2003 | 5 | 0.010 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2003 | 22 | 0.010 |
Why?
|
| Streptococcus pneumoniae | 1 | 2003 | 25 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2003 | 165 | 0.010 |
Why?
|
| Seasons | 1 | 2003 | 105 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 1983 | 69 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 1983 | 177 | 0.010 |
Why?
|
| Infant | 1 | 2003 | 1245 | 0.010 |
Why?
|
| Hepatitis B e Antigens | 1 | 1993 | 1 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1993 | 4 | 0.010 |
Why?
|
| Base Sequence | 1 | 1993 | 20 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1993 | 18 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1993 | 14 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1993 | 17 | 0.010 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 1993 | 12 | 0.010 |
Why?
|
| Hepatitis B virus | 1 | 1993 | 21 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 1993 | 22 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1993 | 53 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1983 | 5 | 0.000 |
Why?
|
| Specimen Handling | 1 | 1983 | 22 | 0.000 |
Why?
|